Xtant Medical Holdings, Inc.
XTNT NYSE· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$0.28
KIRA · Stoqly’s AI analyst, in plain words
- Xtant Medical Holdings, Inc. had $134M of revenue in fiscal 2025, up 14.2% on the year before. Over five years, revenue changed +20.2% a year on average.
- Its operating margin was 5.4%, up 15.7 pts: of every 100 in sales, about 5 is left after running the business.
- Xtant Medical Holdings, Inc. made $5.0M of net profit in fiscal 2025.
- Free cash flow was $10.2M in fiscal 2025, 7.6% of revenue.
- Xtant Medical Holdings, Inc. has $6.0M more cash than debt.
Market cap
$39.4M
P/E
—
Revenue
$134M
Net income
$5.0M
Free cash flow
$10.2M
Operating margin
5.4%
Xtant Medical Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+14.2%
Yes. Sales grew 14.2% last year.
Does it make a profit?
3.7%
A little. It keeps 3.7% of every sale as profit.
Does profit turn into cash?
7.6%
Partly. 7.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xtant Medical Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Xtant Medical Holdings, Inc.
- CIK
- 0001453593
Xtant Medical Holdings, Inc. · XTNT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $55.3M | $58.0M | $91.3M | $117M | $134M |
| Revenue growth | 3.6% | 4.9% | 57.5% | 28.4% | 14.2% |
| Gross margin | 58.8% | 55.4% | 60.8% | 58.2% | 62.9% |
| Operating margin | −7.0% | −11.7% | −11.1% | −10.3% | 5.4% |
| Net income | −$4.8M | −$8.5M | $0.7M | −$16.4M | $5.0M |
| Net margin | −8.8% | −14.6% | 0.7% | −14.0% | 3.7% |
| Diluted EPS | −$0.06 | −$0.09 | $0.01 | −$0.12 | $0.03 |
| Cash | |||||
| Cash from operations | $0.4M | −$5.3M | −$9.5M | −$11.9M | $12.5M |
| Capital expenditure | $2.1M | $1.8M | $1.5M | $4.1M | $2.4M |
| Free cash flow | −$1.7M | −$7.1M | −$11.0M | −$16.0M | $10.2M |
| FCF margin | −3.0% | −12.3% | −12.0% | −13.7% | 7.6% |
| Share count change | 199.8% | 10.1% | 34.8% | 5.4% | 12.3% |
| Debt and strength | |||||
| Cash and short-term investments | $18.2M | $20.3M | $5.7M | $6.2M | $17.1M |
| Debt incl. finance leases | $11.8M | $9.7M | $17.2M | $22.0M | $11.0M |
| Shareholders' equity | $30.9M | $34.2M | $51.3M | $43.0M | $51.0M |
| Net debt / EBITDA | — | — | — | — | −0.5x |
| Current ratio | 4.0x | 3.2x | 2.8x | 2.3x | 2.7x |
| Interest coverage | −3.9x | −4.0x | −3.5x | −2.9x | 2.0x |
| Returns and quality | |||||
| Return on capital | −12.5% | −22.7% | −12.8% | −16.2% | 11.5% |
| Return on equity | −21.4% | −26.1% | 1.5% | −34.9% | 10.6% |
| Return on tangible equity | −17.8% | −27.7% | 1.9% | −60.2% | 11.2% |
| Piotroski F-score | 5 | 2 | 4 | 2 | 8 |
| Altman Z'' | −9.1 | −8.9 | −5.0 | −6.3 | −3.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xtant Medical Holdings, Inc. · XTNT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.28 a share, the company is worth $39.4M.
Source: SEC EDGAR XBRL filings (CIK 0001453593). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.